For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$48.13
Thesis
Scholar Rock develops myostatin-targeting biologics aimed at preserving muscle, with relevance to metabolic and neuromuscular disease. Its lead asset positions the company at the intersection of muscle biology and the obesity treatment landscape.
Catalysts
- Apitegromab regulatory and label progress
- Muscle-preservation data in combination with weight-loss therapies
- Pipeline expansion across neuromuscular and metabolic indications
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 10Financial resultsSEC
8-K filed with items 1.01, 2.02, 7.01 covering financial results and material agreement disclosure.
- Aug 6Securities offeringSEC
Scholar Rock files 424B5 prospectus supplement.
- Aug 6Financial resultsSEC
8-K item 2.02 filing on results of operations.
- May 7Financial resultsSEC
8-K filing (items 2.02/7.01/9.01) reporting financial results.